The integration of chemotherapy, radiotherapy and transurethral surgery in bladder-sparing approaches for patients with invasive tumors.
作者信息
Shipley W U, Kaufman D S, Heney N M, Griffin P P, Althausen A F, Prout G R
机构信息
Radiation Medicine Service, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston 02114.
出版信息
Prog Clin Biol Res. 1990;353:85-94.
PMID:2217430
Abstract
摘要
相似文献
1
2
Bladder-sparing therapy for muscle-infiltrating bladder cancer.肌肉浸润性膀胱癌的保膀胱治疗
Nat Clin Pract Urol. 2008 Jul;5(7):368-75. doi: 10.1038/ncpuro1145. Epub 2008 Jun 17.
3
Upfront chemotherapy in invasive bladder cancer.浸润性膀胱癌的 upfront 化疗。
Prog Clin Biol Res. 1992;378:111-6.
4
Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties.采用根治性放疗治疗肌层浸润性膀胱癌的化疗：仍存在不确定性。
Nat Clin Pract Oncol. 2008 Aug;5(8):444-54. doi: 10.1038/ncponc1159. Epub 2008 Jun 24.
5
Current status of bladder cancer protocols in the EORTC Genito-Urinary Group.欧洲癌症研究与治疗组织泌尿生殖系统组中膀胱癌治疗方案的现状
Prog Clin Biol Res. 1984;162B:429-39.
6
Clinical trials in superficial and invasive bladder cancer.
Turk J Pediatr. 1984;26(1-4):251-63.
7
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.放射肿瘤学组（RTOG）针对肌层浸润性膀胱癌患者开展的I-II期研究（99-06），这些患者接受经尿道手术、紫杉醇、顺铂及每日两次放疗，随后进行选择性膀胱保留或根治性膀胱切除术及辅助化疗。
Urology. 2009 Apr;73(4):833-7. doi: 10.1016/j.urology.2008.09.036. Epub 2008 Dec 18.
8
9
Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
Prog Clin Biol Res. 1984;162B:397-427.
10
Adjuvant chemotherapy of bladder cancer.膀胱癌的辅助化疗。
Prog Clin Biol Res. 1988;260:545-9.
Zotero 插件